INT257400

Context Info Confidence 0.50 First Reported 2008 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 3 Total Number 3 Disease Relevance 0.79 Pain Relevance 0.78

cytosol (FGD1) signal transduction (FGD1) Golgi apparatus (FGD1) plasma membrane (FGD1) cytoskeleton (FGD1) nucleus (FGD1)

FGD1 (Homo sapiens)

Pain Link Frequency Relevance Heat addiction 32 95.36 depression 10 93.56 Potency 6 90.96 alcohol 30 86.44 Analgesic 14 68.32 headache 4 66.40 cINOD 4 60.80 diclofenac 1 57.76 Pain 21 5.00 cocaine 4 5.00

Disease Link Frequency Relevance Heat Aggression 31 94.72 Depression 10 93.56 Hallucination 2 93.08 Reprotox - General 3 14 80.48 Headache 4 66.40 INFLAMMATION 1 60.40 Alcohol Intoxication 2 50.68 Renal Disease 18 50.00 Pain 21 5.00 Acne 12 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

The development of late combined drug use starting with AAS

Positive_regulation (starting) of Gene_expression (with) of AAS

1) Confidence 0.50 Published 2008 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2612649 Disease Relevance 0.32 Pain Relevance 0.38

By the age of 25, after five years of AAS abuse, he was tested for AAS use at the gym at which he trained.

Positive_regulation (tested) of Gene_expression (use) of AAS

2) Confidence 0.43 Published 2008 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2612649 Disease Relevance 0.41 Pain Relevance 0.25

UGTs not only contribute to AAS glucuronidation but they also act as conjugating enzymes for various other pharmaceutical drugs [35,43].

Positive_regulation (contribute) of Gene_expression (glucuronidation) of AAS

3) Confidence 0.07 Published 2010 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2877023 Disease Relevance 0.06 Pain Relevance 0.15

General Comments

This test has worked.